Tag: NEJM

NEJM

DTC Advertising

NEJM: Drug Price Information in DTC Ads Raises Public Health, Legal Concerns

NEJM: Drug Price Information in DTC Ads Raises Public Health, Legal Concerns

Nov. 19, 2018 – In a featured “Perspective” article in The New England Journal of Medicine (NEJM) this week, Stacie B. Dusetzina, Ph.D., and Michelle M. Mello, J.D., Ph.D., state that although providing cost information about prescription drugs is valuable, mandating that companies use the wholesale acquisition cost (WAC) in direct-to-consumer (DTC) ads “raises substantial […]

Read more